Natural Product (NP) Details
General Information of the NP (ID: NP0478) | |||||
---|---|---|---|---|---|
Name |
Xanthohumol
|
||||
Synonyms |
Xanthohumol; 6754-58-1; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 569-83-5; UNII-T4467YT1NT; T4467YT1NT; CHEBI:66331; 2',4,4'-trihydroxy-6'-methoxy-3'-prenylchalcone; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; (2E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one; (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; XANTHOHUMO; 2',4,4'-Trihydroxy-3'-prenyl-6'-methoxychalcone; SCHEMBL143683; CHEMBL253896; MEGxp0_000104; ACon1_001634; CHEBI:94745; DTXSID00893171; Xanthohumol(Random Configuration); HMS3886H19; BCP18498; ZINC5158937; 0397AC; BDBM50384998; LMPK12120294; MFCD00210576; s7889; AKOS016010098; CCG-268086; DB15359; MCULE-7307777782; (E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-hydroxyphenyl)propenone; SMP2_000278; NCGC00180304-01; AC-31276; BS-17392; W2672; C16417; Q408088; BRD-K77390737-001-01-6; Q27166535; Xanthohumol, primary pharmaceutical reference standard; Xanthohumol from hop (Humulus lupulus), >=96% (HPLC); (2E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one; 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-but-2-enyl)-phenyl]-3-(4-hydroxy-phenyl)-propenone; 2-Propen-1-one, 1-(2,4-hydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-, (E)-
Click to Show/Hide
|
||||
Species Origin | Humulus lupulus ... | Click to Show/Hide | |||
Humulus lupulus | |||||
Disease | Acute lung injury [ICD-11: NB32] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C21H22O5
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C
|
||||
InChI |
1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+
|
||||
InChIKey |
ORXQGKIUCDPEAJ-YRNVUSSQSA-N
|
||||
CAS Number |
CAS 6754-58-1
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Praziquantel | Flatworm infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | CD44 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TFRC | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Six- to eight-week-old male Syrian golden hamsters were used in this study. | |||||
Experimental
Result(s) |
XN administered in combination with PZ could efficiently prevent CCA development and hence provide potential chemopreventive benefits in Ov-induced cholangiocarcinogenesis. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Acetyl-CoA carboxylase kinase 1 (PRKAA1) | Molecule Info | [3] | |
Acetyl-CoA carboxylase kinase 2 (PRKAA2) | Molecule Info | [3] | ||
C-X-C motif chemokine 1 (CXCL1) | Molecule Info | [4] | ||
Glycogen synthase kinase-3 beta (GSK-3B) | Molecule Info | [1] | ||
Intercellular adhesion ICAM-1 (ICAM1) | Molecule Info | [5] | ||
Monocyte secretory JE (CCL2) | Molecule Info | [4] | ||
NAD-dependent deacetylase sirtuin-1 (SIRT1) | Molecule Info | [6] | ||
Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [3] | ||
KEGG Pathway | ErbB signaling pathway | Click to Show/Hide | ||
2 | Chemokine signaling pathway | |||
3 | Cell cycle | |||
4 | PI3K-Akt signaling pathway | |||
5 | Wnt signaling pathway | |||
6 | Hedgehog signaling pathway | |||
7 | Axon guidance | |||
8 | Hippo signaling pathway | |||
9 | Focal adhesion | |||
10 | Signaling pathways regulating pluripotency of stem cells | |||
11 | T cell receptor signaling pathway | |||
12 | B cell receptor signaling pathway | |||
13 | Neurotrophin signaling pathway | |||
14 | Dopaminergic synapse | |||
15 | Insulin signaling pathway | |||
16 | Melanogenesis | |||
17 | Prolactin signaling pathway | |||
18 | Thyroid hormone signaling pathway | |||
19 | Non-alcoholic fatty liver disease (NAFLD) | |||
20 | Alzheimer's disease | |||
21 | Hepatitis C | |||
22 | Measles | |||
23 | Influenza A | |||
24 | HTLV-I infection | |||
25 | Epstein-Barr virus infection | |||
26 | Pathways in cancer | |||
27 | Colorectal cancer | |||
28 | Endometrial cancer | |||
29 | Prostate cancer | |||
30 | Basal cell carcinoma | |||
31 | Cytokine-cytokine receptor interaction | |||
32 | NOD-like receptor signaling pathway | |||
33 | TNF signaling pathway | |||
34 | Chagas disease (American trypanosomiasis) | |||
35 | Malaria | |||
36 | Herpes simplex infection | |||
37 | Rheumatoid arthritis | |||
38 | NF-kappa B signaling pathway | |||
39 | Cell adhesion molecules (CAMs) | |||
40 | Natural killer cell mediated cytotoxicity | |||
41 | Leukocyte transendothelial migration | |||
42 | African trypanosomiasis | |||
43 | Staphylococcus aureus infection | |||
44 | Viral myocarditis | |||
45 | Protein processing in endoplasmic reticulum | |||
46 | FoxO signaling pathway | |||
47 | AMPK signaling pathway | |||
48 | Glucagon signaling pathway | |||
49 | Amphetamine addiction | |||
50 | MicroRNAs in cancer | |||
NetPath Pathway | IL9 Signaling Pathway | Click to Show/Hide | ||
2 | IL5 Signaling Pathway | |||
3 | IL1 Signaling Pathway | |||
4 | TSH Signaling Pathway | |||
5 | TWEAK Signaling Pathway | |||
6 | IL4 Signaling Pathway | |||
7 | TNFalpha Signaling Pathway | |||
8 | TSLP Signaling Pathway | |||
9 | Leptin Signaling Pathway | |||
10 | RANKL Signaling Pathway | |||
11 | IL6 Signaling Pathway | |||
12 | IL2 Signaling Pathway | |||
13 | ID Signaling Pathway | |||
Panther Pathway | Alzheimer disease-presenilin pathway | Click to Show/Hide | ||
2 | Angiogenesis | |||
3 | Cadherin signaling pathway | |||
4 | Hedgehog signaling pathway | |||
5 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
6 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
7 | Interleukin signaling pathway | |||
8 | PDGF signaling pathway | |||
9 | PI3 kinase pathway | |||
10 | Wnt signaling pathway | |||
11 | Ras Pathway | |||
12 | CCKR signaling map ST | |||
13 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
14 | p53 pathway | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Degradation of beta catenin | |||
3 | Reelin signaling pathway | |||
4 | Presenilin action in Notch and Wnt signaling | |||
5 | Integrin-linked kinase signaling | |||
6 | CDC42 signaling events | |||
7 | LKB1 signaling events | |||
8 | Canonical Wnt signaling pathway | |||
9 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
10 | Glucocorticoid receptor regulatory network | |||
11 | C-MYC pathway | |||
12 | Regulation of Androgen receptor activity | |||
13 | BMP receptor signaling | |||
14 | Hedgehog signaling events mediated by Gli proteins | |||
15 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
16 | Validated transcriptional targets of deltaNp63 isoforms | |||
17 | Aurora A signaling | |||
18 | Insulin-mediated glucose transport | |||
19 | Class I PI3K signaling events mediated by Akt | |||
20 | p53 pathway | |||
21 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
22 | GMCSF-mediated signaling events | |||
23 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
24 | AP-1 transcription factor network | |||
25 | IL23-mediated signaling events | |||
26 | Thromboxane A2 receptor signaling | |||
27 | amb2 Integrin signaling | |||
28 | Beta2 integrin cell surface interactions | |||
29 | p73 transcription factor network | |||
30 | Signaling events mediated by HDAC Class III | |||
31 | E2F transcription factor network | |||
32 | HIF-2-alpha transcription factor network | |||
33 | Signaling events mediated by HDAC Class I | |||
34 | FoxO family signaling | |||
35 | Regulation of retinoblastoma protein | |||
Reactome | Degradation of beta-catenin by the destruction complex | Click to Show/Hide | ||
2 | AKT phosphorylates targets in the cytosol | |||
3 | Regulation of HSF1-mediated heat shock response | |||
4 | CRMPs in Sema3A signaling | |||
5 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
6 | S33 mutants of beta-catenin aren't phosphorylated | |||
7 | S37 mutants of beta-catenin aren't phosphorylated | |||
8 | S45 mutants of beta-catenin aren't phosphorylated | |||
9 | T41 mutants of beta-catenin aren't phosphorylated | |||
10 | Degradation of GLI2 by the proteasome | |||
11 | Constitutive Signaling by AKT1 E17K in Cancer | |||
12 | Chemokine receptors bind chemokines | |||
13 | ATF4 activates genes | |||
14 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
15 | Integrin cell surface interactions | |||
16 | Interferon gamma signaling | |||
17 | RORA activates gene expression | |||
18 | Circadian Clock | |||
WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
2 | Senescence and Autophagy in Cancer | |||
3 | Notch Signaling Pathway | |||
4 | Glycogen Metabolism | |||
5 | Insulin Signaling | |||
6 | Wnt Signaling Pathway | |||
7 | Wnt Signaling Pathway and Pluripotency | |||
8 | IL-6 signaling pathway | |||
9 | Wnt Signaling Pathway Netpath | |||
10 | Copper homeostasis | |||
11 | Focal Adhesion | |||
12 | Hair Follicle Development: Induction (Part 1 of 3) | |||
13 | Cardiac Hypertrophic Response | |||
14 | Degradation of beta-catenin by the destruction complex | |||
15 | T-Cell Receptor and Co-stimulatory Signaling | |||
16 | Cardiac Progenitor Differentiation | |||
17 | BDNF signaling pathway | |||
18 | Corticotropin-releasing hormone | |||
19 | B Cell Receptor Signaling Pathway | |||
20 | IL17 signaling pathway | |||
21 | Neural Crest Differentiation | |||
22 | Alzheimers Disease | |||
23 | IL-7 Signaling Pathway | |||
24 | Regulation of Microtubule Cytoskeleton | |||
25 | TWEAK Signaling Pathway | |||
26 | Leptin signaling pathway | |||
27 | Semaphorin interactions | |||
28 | Cell Cycle | |||
29 | MicroRNAs in cardiomyocyte hypertrophy | |||
30 | Androgen receptor signaling pathway | |||
31 | IL-5 Signaling Pathway | |||
32 | IL1 and megakaryotyces in obesity | |||
33 | Activation of Genes by ATF4 | |||
34 | Spinal Cord Injury | |||
35 | Oncostatin M Signaling Pathway | |||
36 | TNF alpha Signaling Pathway | |||
37 | IL-1 signaling pathway | |||
38 | GPCR ligand binding | |||
39 | Folate Metabolism | |||
40 | Vitamin B12 Metabolism | |||
41 | Selenium Micronutrient Network | |||
42 | Type II interferon signaling (IFNG) | |||
43 | Human Complement System | |||
44 | Interleukin-11 Signaling Pathway | |||
45 | RANKL/RANK Signaling Pathway | |||
46 | Integrin cell surface interactions | |||
47 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
48 | Oxidative Stress | |||
49 | Transcriptional activation by NRF2 | |||
50 | NRF2 pathway | |||
51 | Nuclear Receptors Meta-Pathway | |||
52 | Aryl Hydrocarbon Receptor Pathway | |||
53 | Mesodermal Commitment Pathway | |||
54 | Aryl Hydrocarbon Receptor | |||
55 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
56 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
57 | Integrated Pancreatic Cancer Pathway | |||
58 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
59 | Integrated Breast Cancer Pathway | |||
60 | SREBP signalling |


